Increasing numbers of midlife vascular risk factors obesity, smoking, hypertension, diabetes and high cholesterol associate with brain amyloid deposition in later life.
Dr. Robert J Chilton, MD, argues that new diabetes treatments showing cardiovascular benefit require a different role of the cardiologist. The SGLT2 inhibitor empagliflozin, for example, shows both cardiovascular and renal protection, in addition to lowering glucose.
The EXPERT tool specifies ideal exercise type, intensity, frequency, and duration needed to prevent a first or repeat cardiovascular event.
In diabetic patients at high cardiovascular risk, empagliflozin, when compared with placebo, was not associated with either a reduction or an increase in the risk of cerebrovascular events.
A new meta-analysis provide insights in statin use for primary prevention of the elderly, however, it also leaves critical questions unanswered that are relevant for clinical practice.
PCSK9 Expert Opinions By combining all recent insights on treatment with PCSK9 inhibitors, prof. Stephen Nicholls argues that the PCSK9 outcome trials reinforce the concept that patients with high CV risk may benefit from PCSK9 inhibiting treatment.
In high CV risk patients, lowering SBP to less than 130 mmHg or DBP to less than 75 mmHg, associates with increased rates for CV death, myocardial infarction and heart failure, but not stroke.
Natriuretic peptide levels in HFpEF patients associate with adverse outcomes and patients with low NP levels benefited from spironolactone therapy in particular.
Analysis of new users of rivaroxaban or dabigatran, aspirin and VKAs in CPRD reveals a two-fold increased risk of AMI in current users of DOAC or aspirin, as compared with VKA.
In a large cohort study of 30 years, heart failure was associated with an increased risk of ischaemic stroke, intracerebral and subarachnoid haemorrhage, especially in the short term.
Angiopoietin-like protein 3 mutations relate to coronary plaque, lower lipid and triglyceride levels and reduced CAD risk and levels of ANGPTL3 protein associate with risk for myocardial infarction.
Levels of HDL with or without apoC-III both associated differently with the amount of physical activity or anthropometrical measures, such as waist and hip circumference, BMI and fat mass.